{"id":"mitoxantrone-cytarabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity (mitoxantrone-related)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1417019","moleculeType":"Small molecule","molecularWeight":"517.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mitoxantrone is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA repair, while cytarabine is a nucleoside analog that inhibits DNA polymerase and gets incorporated into DNA, causing chain termination. Together, they create a synergistic cytotoxic effect against rapidly dividing hematologic malignancies.","oneSentence":"Mitoxantrone and cytarabine are chemotherapy agents that work together to inhibit DNA synthesis and induce apoptosis in leukemic cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:23.409Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"}]},"trialDetails":[{"nctId":"NCT03983824","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-05","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT02523976","phase":"PHASE2","title":"Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2015-08-01","conditions":"Acute,Leukemia, Lymphoid","enrollment":30},{"nctId":"NCT03182244","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2017-10-25","conditions":"AML With FLT3 Mutation","enrollment":276},{"nctId":"NCT06660368","phase":"PHASE2","title":"BCL2i CLAG-M in R/R Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-26","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":52},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT05657639","phase":"PHASE2","title":"CAV Regimen for R/R AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT05955261","phase":"PHASE2","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-07-25","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT01371981","phase":"PHASE3","title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm","enrollment":1645},{"nctId":"NCT06451861","phase":"PHASE2","title":"Randomized Study of ABC-14 Regimen Compared With \"3+7\" Standard Induction Therapy or AB-14 for ND AML","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-08-21","conditions":"Acute Myeloid Leukemia","enrollment":240},{"nctId":"NCT03118466","phase":"PHASE2","title":"Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-09-25","conditions":"AML","enrollment":41},{"nctId":"NCT04797767","phase":"PHASE1, PHASE2","title":"Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-02-04","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":62},{"nctId":"NCT06621212","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-05","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":72},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06265545","phase":"NA","title":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-02-22","conditions":"AML, Refractory, Relapsed","enrollment":120},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT02521493","phase":"PHASE3","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-12-23","conditions":"Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome","enrollment":280},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT05054543","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML","status":"TERMINATED","sponsor":"Apollomics Inc.","startDate":"2021-11-17","conditions":"Relapsed/Refractory AML","enrollment":140},{"nctId":"NCT04839341","phase":"PHASE1","title":"Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients","status":"COMPLETED","sponsor":"Apollomics Inc.","startDate":"2021-02-24","conditions":"Relapsed/Refractory AML","enrollment":12},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT05941585","phase":"NA","title":"Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-08-08","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT01184898","phase":"NA","title":"Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"AML","enrollment":36},{"nctId":"NCT00410423","phase":"PHASE1, PHASE2","title":"Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-01","conditions":"Relapsed Acute Leukemia, Refractory Acute Leukemia","enrollment":55},{"nctId":"NCT02632708","phase":"PHASE1","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-12-31","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":153},{"nctId":"NCT03150004","phase":"PHASE2","title":"Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-14","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":53},{"nctId":"NCT04778410","phase":"PHASE2","title":"Study of Magrolimab Combinations in Participants With Myeloid Malignancies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Myeloid Malignancies","enrollment":54},{"nctId":"NCT06757478","phase":"","title":"A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-05-01","conditions":"Lymphoma Patient","enrollment":30},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT06651866","phase":"PHASE1","title":"Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-12-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT05603884","phase":"PHASE2","title":"VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-12-01","conditions":"Leukemia, Myeloid, Acute, AML Stage, Adult","enrollment":66},{"nctId":"NCT06741722","phase":"PHASE2","title":"Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-10-31","conditions":"AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05904106","phase":"PHASE2","title":"Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2024-04-07","conditions":"Acute Myeloid Leukemia","enrollment":146},{"nctId":"NCT03441048","phase":"PHASE1","title":"Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-05-22","conditions":"Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT06621199","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-08","conditions":"Acute Myeloid Leukemia","enrollment":42},{"nctId":"NCT02484391","phase":"PHASE1","title":"CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-09","conditions":"Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02907359","phase":"PHASE3","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-01-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":417},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT06007911","phase":"PHASE1","title":"Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2024-08-31","conditions":"Relapsed Adult AML, Refractory AML","enrollment":""},{"nctId":"NCT03616470","phase":"PHASE3","title":"Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"GlycoMimetics Incorporated","startDate":"2018-10-15","conditions":"Acute Myeloid Leukemia","enrollment":388},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT02400281","phase":"PHASE1, PHASE2","title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT06447090","phase":"PHASE2","title":"VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-12","conditions":"Relapse Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06434662","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-02-29","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":34},{"nctId":"NCT06345365","phase":"PHASE3","title":"MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2024-01-18","conditions":"Acute Myeloid Leukaemia","enrollment":154},{"nctId":"NCT06329999","phase":"NA","title":"A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-02-03","conditions":"Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia","enrollment":78},{"nctId":"NCT04330820","phase":"PHASE1, PHASE2","title":"Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2020-04-06","conditions":"Relapsed Adult AML, Refractory AML","enrollment":55},{"nctId":"NCT01497002","phase":"PHASE3","title":"Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2005-04","conditions":"Acute Myeloid Leukaemia","enrollment":1222},{"nctId":"NCT02461537","phase":"PHASE3","title":"Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML","status":"COMPLETED","sponsor":"DKMS gemeinnützige GmbH","startDate":"2015-09-17","conditions":"Acute Myeloid Leukemia","enrollment":281},{"nctId":"NCT06211452","phase":"PHASE3","title":"Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2007-08-01","conditions":"AML, Pediatric AML","enrollment":258},{"nctId":"NCT04196010","phase":"PHASE1","title":"Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-05-08","conditions":"Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT02626338","phase":"PHASE1, PHASE2","title":"Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2016-02","conditions":"Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":16},{"nctId":"NCT02520011","phase":"PHASE2","title":"Alvocidib Biomarker-driven Phase 2 AML Study","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2016-03-14","conditions":"Acute Myeloid Leukemia","enrollment":104},{"nctId":"NCT02583893","phase":"PHASE2","title":"Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2015-10-07","conditions":"Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia","enrollment":39},{"nctId":"NCT03531918","phase":"PHASE1, PHASE2","title":"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-09-14","conditions":"Acute Myeloid Leukemia","enrollment":66},{"nctId":"NCT05313958","phase":"PHASE2, PHASE3","title":"Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-01","conditions":"Leukemia, Monocytic, Acute, Pediatric AML","enrollment":43},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT02728050","phase":"PHASE1, PHASE2","title":"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-12-01","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome","enrollment":84},{"nctId":"NCT02299518","phase":"PHASE1","title":"Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Alice Mims","startDate":"2015-05-18","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":23},{"nctId":"NCT05876832","phase":"PHASE3","title":"A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)","status":"NOT_YET_RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2023-06-15","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":312},{"nctId":"NCT05330377","phase":"PHASE1","title":"GM-CLAG in Relapsed/Refractory FLT3-mutated AML","status":"WITHDRAWN","sponsor":"Ayman H Qasrawi","startDate":"2023-03","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT05814718","phase":"NA","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Autologous Stem Cell Transplantation, Conditioning","enrollment":122},{"nctId":"NCT05814731","phase":"NA","title":"Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Haploidentical Stem Cell Transplantation, Conditioning","enrollment":264},{"nctId":"NCT00199069","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)","status":"COMPLETED","sponsor":"Goethe University","startDate":"1993-04","conditions":"Adult Acute Lymphocytic Leukemia","enrollment":720},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT03504410","phase":"PHASE3","title":"Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML","status":"TERMINATED","sponsor":"Cornerstone Pharmaceuticals","startDate":"2018-11-12","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT00003407","phase":"PHASE2","title":"Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2001-02-13","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT05681403","phase":"NA","title":"Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-01-15","conditions":"Lymphoma, Autologous Hematopoietic Stem Cell Transplantation","enrollment":53},{"nctId":"NCT01154439","phase":"PHASE1","title":"Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2010-10","conditions":"Leukemia","enrollment":11},{"nctId":"NCT01842672","phase":"PHASE1, PHASE2","title":"Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2013-03","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma","enrollment":41},{"nctId":"NCT00866918","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-03-09","conditions":"Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm","enrollment":106},{"nctId":"NCT02686593","phase":"PHASE2","title":"Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-02-01","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT01700946","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-04-15","conditions":"Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT03989713","phase":"PHASE2","title":"Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD","status":"TERMINATED","sponsor":"Prof. Dr. Richard F Schlenk","startDate":"2020-07-17","conditions":"AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)","enrollment":11},{"nctId":"NCT03173612","phase":"NA","title":"The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":132},{"nctId":"NCT01550185","phase":"PHASE1","title":"Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-05","conditions":"Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)","enrollment":10},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT02200978","phase":"PHASE4","title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","status":"COMPLETED","sponsor":"South China Children's Leukemia Group","startDate":"2011-09","conditions":"Childhood Acute Promyelocytic Leukemia","enrollment":176},{"nctId":"NCT03563560","phase":"PHASE1","title":"A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2018-05-15","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT03012672","phase":"PHASE2","title":"Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-12-30","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":50},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT02910752","phase":"PHASE1, PHASE2","title":"CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation","status":"SUSPENDED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-09","conditions":"Leukemia","enrollment":20},{"nctId":"NCT02756572","phase":"PHASE2","title":"Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-09-22","conditions":"Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm","enrollment":30},{"nctId":"NCT05100303","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-12","conditions":"Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mitoxantrone, Cytarabine","genericName":"Mitoxantrone, Cytarabine","companyName":"The First Hospital of Jilin University","companyId":"the-first-hospital-of-jilin-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mitoxantrone and cytarabine are chemotherapy agents that work together to inhibit DNA synthesis and induce apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}